The possibility of using biomedical cell product in the treatment of chronic glomerulonephritis

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The basic principles of rational treatment of glomerulonephritis are considered, based on etiology, clinical manifestations and pathomorphological variants of its different forms. Today it has been established that glomerulonephritis can be primary (the etiology is usually unknown) and secondary, when the disease occurs against the background of concomitant pathology (systemic lupus erythematosus, vasculitis, hepatitis, oncological diseases, chronic viral and bacterial infections). The participation of various pathological, genetic and systemic factors in the development of various forms of glomerulonephritis has been shown. The characteristic clinical picture of manifestations of different forms of the disease and the degree of involvement of different renal structures in them are described. Against the background of the severity of the course and prevalence of various forms of glomerulonephritis, it is especially important to develop therapeutic approaches aimed at the full restoration of kidney function and cure of patients. One of such approaches is the use of biomedical cell products based on allogenic mesenchymal multipotent stromal cells and hematopoietic stromal cells. A number of studies have confirmed that the best results can be achieved with the use of cell products in complex therapies with standard treatment methods (use of cytostatics and steroid anti-inflammatory drugs) and alternative drug approaches (combination of monoclonal antibodies and polyenzyme drugs). At the same time, the use of standard and alternative techniques does not lead to a complete recovery of patients, but only transfers the course of the disease from the exacerbation phase to remission. The relevance of further development of biomedical cell products of allogeneic mesenchymal multipotent bone marrow stromal cells is shown, verification of their safety and efficacy in preclinical and clinical studies.

Full Text

Restricted Access

About the authors

Lidia P. Sigareva

Saint Petersburg State Pediatric Medical University

Author for correspondence.
Email: sigaryowa@yandex.ru

junior research associate

Russian Federation, Saint Petersburg

Arina A. Kokorina

Military Medical Academy named after S.M. Kirov

Email: el-kaa@mail.ru

junior research associate

Russian Federation, Saint Petersburg

Albina A. Kondartenko

Military Medical Academy named after S.M. Kirov

Email: kondraa24@gmail.com

junior research associate

Russian Federation, Saint Petersburg

Pavel A. Slizhov

Military Medical Academy named after S.M. Kirov

Email: maidel@bk.ru

junior research associate

Russian Federation, Saint Petersburg

Ekaterina V. Ekaterina

Saint Petersburg State Pediatric Medical University, Institute of cytology Russian Academy of Science

Email: 4evamkh@gmail.com

candidate of biology

Russian Federation, Saint Petersburg

Viktor N. Alexandrov

Saint Petersburg State Pediatric Medical University, Military Medical Academy named after S.M. Kirov

Email: vnaleks9@yandex.ru

doctor of medical sciences, professor

Russian Federation, Saint Petersburg

Anton A. Solovyov

Saint Petersburg State Pediatric Medical University

Email: vnaleks9@yandex.ru

candidate of medical sciences

Russian Federation, Saint Petersburg

References

  1. Tomilina NA, Bikbetov BT. Jepidemiologija hronicheskoj pochechnoj nedostatochnosti i novye podhody k klassifikacii i ocenke tjazhesti hronicheskih progressirujushhih zabolevanij pochek. Terapevticheskij arhiv. 2005;77(6):87–92. (In Russ.)
  2. Poulsom R. Experimental models of renal disease. Int J Exp Pathol. 2011;92:141–142. doi: 10.1111/j.1365-2613.2011.00776.x
  3. Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney Int. 2014;86:905–914. doi: 10.1038/ki.2014.49
  4. Prihodina LS, Dlin VV, Ignatova MS. Glomerulonefrit pervichnyj. Detskaja nefrologija: rukovodstvo dlja vrachej. 2011:263–268.(In Russ.)
  5. Karras A, Jayne D. New biologics for glomerular disease on the horizon. Nephron Clin Pract. 2014;128:283–291. doi: 10.1159/000368593
  6. Meiling J, Xie Y, Li Q, et al. Stem Cell-Based Cell Therapy for Glomerulonephritis. BioMed Research International. 2014;5:1–15. doi: 10.1155/2014/124730
  7. Chadban SJ, Atkins RC. Glomerulonephritis. The Lancet. 2005;365:1797–1806. doi: 10.1016/S0140-6736(05)66583-X
  8. William GC. Pathogenesis and treatment of glomerulonephritis-an update. J Bras Nefrol. 2016;38:107–122. doi: 10.5935/0101-2800.20160016
  9. Ar’ev AL, Izotova AB. Sovremennye predstavlenija o patogeneze idiopaticheskogo membranoznogo glomerulonefrita. Nefrologija. 2004;4:92–95. (In Russ.)
  10. Papajan AV, Savenkova ND. Klinicheskaja nefrologija detskogo vozrasta: rukovodstvo dlja vrachej. Saint Petersbourg: Levsha; 2008. (In Russ.)
  11. Floege J, Amann K. Primary glomerulonephritis. The Lancet. 2016;14:2036–2048. doi: 10.1016/S0140-6736(16)00272-5
  12. Chevalier RL. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am J Physiol Renal Physiol. 2016;311(1):145–161. doi: 10.1152/ajprenal.00164.2016
  13. Jushina IA, Kalmykova EV, Nekipelova EV. Ocenka roli geneticheskih i immunologicheskih faktorov v formirovanii hronicheskoj pochechnoj nedostatochnosti na fone hronicheskogo glomerulonefrita. Kurskij nauchno-prakticheskij vestnik “Chelovek i ego zdorov’e”. 2008;2:117–124. (In Russ.)
  14. D’Souza Z, McAdoo SP, Smith J, et al. Experimental crescentic glomerulonephritis: a new bicongenic rat model. Dis Model Mech. 2013;6:1477–1486. doi: 10.1242/dmm.012328
  15. Bel’skih AN, Golota AS, Krassij AB. Kletochnye tehnologii v nefrologii: sovremennoe sostojanie i perspektivy dlja voennoj mediciny. Voenno-medicinskij zhurnal. 2015;9(336):55–60. (In Russ.)
  16. Mestecky J, Raska M, Julian BA, et al. IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol. 2013;8:217–240. doi: 10.1146/annurev-pathol-011110-130216
  17. Jegatheesan D, Nath K, Reyaldeen R, et al. Epidemiology of biopsy-proven glomerulonephritis in Queensland adults. Nephrology. 2016;21:28–34. doi: 10.1111/nep.12559
  18. Shah Y, Mohiuddin A, Sluman C, et al. Rituximab in anti-glomerular basement membrane disease. QJM. 2012;105:195–197. doi: 10.1093/qjmed/hcr001
  19. Eunkyeong J, Jeong M, Kim S, et al. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development. Cell Transplantat. 2016;25:1–15. doi: 10.3727/096368915X688173
  20. Mariam PA, Fervenza FC, Vriese An S De, et al. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association? J Nephrol. 2016;29:203–209. doi: 10.1007/s40620-015-0218-9
  21. Jackson SJ, Steer AC, Campbell H. Systematic review: Estimation of global burden of nonsuppurative sequelae of upper respiratory tract infection: rheumatic fever and poststreptoccocal glomerulonephritis. Trop Med Int Health. 2011;16:2–11. doi: 10.1111/j.1365-3156.2010.02670.x
  22. Kanjanabuch T, Kittikowit W, Eiam-Ong S. An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol. 2009;5:259–269. doi: 10.1038/nrneph.2009.44
  23. Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney International. 2014;86:905–914. doi: 10.1038/ki.2014.49
  24. Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant. 2001;16:1364–1367. doi: 10.1093/ndt/16.7.1364
  25. Sadovnikova IV. Vozmozhnye oslozhnenija pri steroidnoj terapii hronicheskogo glomerulonefrita v pediatricheskoj praktike. Sovremennye tehnologii v medicine. 2009;2:79–81. (In Russ.)
  26. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12. doi: 10.1053/ajkd.2003.50007
  27. Sethi S, Fervenza FC. Standardized classification and reporting of glomerulonephritis. Nephrol Dial Transplant. 2019;34:193–199. doi: 10.1093/ndt/gfy220
  28. Dahan K, Boffa J. Membranous Glomerulonephritis. Nephrol Dial Transplant. 2020:35(4):549–551. doi: 10.1093/ndt/gfz139
  29. Mathis D, Benoist C. Back to central tolerance. Immunity. 2004;20:509–516. doi: 10.1016/s1074-7613(04)00111-6
  30. Si-Yang W, Bu R, Zhang Q, et al. Clinical, Pathological, and Prognostic Characteristics of Glomerulonephritis Related to Staphylococcal Infection. Medicine. 2016;95:1–7. doi: 10.1097/MD.0000000000003386.
  31. Muhin NA. Racional’naja farmakoterapija v nefrologii. Rukovodstvo dlja praktikujushhih vrachej. Moscow: Literra; 2006. (In Russ.)
  32. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in the general community: the AusDiab Kidney Study. J Am Soc Nephrol. 2003;14:5131–5138. doi: 10.1097/01.asn.0000070152.11927.4a
  33. Burova LA, Gavrilova EA, Pigarevskij PV. Svjazyvanie streptokokkami gruppy A tipa M12 immunnyh kompleksov: rol’ dannogo svjazyvanija v patogeneze jeksperimental’nogo glomerulonefrita. Medicinskaja immunologija. 2006;8:124–125. (In Russ.)
  34. Kudrjashov SI, Leont’eva EV, Karzakova LM. Sovremennye osobennosti kliniko-immunologicheskih projavlenij glomerulonefrita. Klinicheskaja i profilakticheskaja medicina. 2017;2:13–18. (In Russ.)
  35. Gordeev IG, Soboleva VN, Volov NA. Varianty techenija bystroprogressirujushhego glomerulonefrita: kak i chem lechit’. Lechebnoe delo. 2018;1:26–31. (In Russ.)
  36. Klochkov ND. Izbrannye lekcii po chastnoj patologicheskoj anatomii. Saint Petersbourg:Voenno-medicinskaja akademija imeni S.M. Kirova;1992. (In Russ.)
  37. Smirnov AV, Shilov EM, Kozlovskaja NL. Nefrologija. Klinicheskie rekomendacii. Moscow: GEOTAR-Media; 2020. (In Russ.)
  38. Smirnov AV, Dobronravov VA, Sipovskij VG. Klinicheskie rekomendacii po diagnostike, lecheniju i prognozu membranoproliferativnogo glomerulonefrita. Nefrologija. 2014;18(6):82–93. (In Russ.)
  39. Avtonomova OI, Karzakova LM, Geranjushkina EI. Osobennosti immuno-gematologicheskih projavlenij ostrogo i hronicheskogo techenija glomerulonefrita. Vestnik Chuvashskogo universiteta. 2013;3:323–329. (In Russ.)
  40. Novakova ON, Nekipelova EV, Jakunchenko TI. Rol’ genov-kandidatov v progressirovanii hronicheskogo glomerulonefrita. Nauchnye vedomosti. Serija Medicina. Farmacija. 2016;12:118–123. (In Russ.)
  41. Shulutko BI, Makarenko SV. Ostryj glomerulonefrit, i ne tol’ko, v XXI veke. Nefrologija. 2015;6(19):14–19. (In Russ.)
  42. Muravleva LE, Molotov-Luchanskij VB, Kljuev DA. Gemostaz pri hronicheskoj bolezni pochek. Sovremennye problemy nauki i obrazovanija. 2010;4:36–42. (In Russ.)
  43. Muhin IV. Sravnitel’naja jeffektivnost’ lechenija hronicheskogo glomerulonefrita. Nefrologija. 2001;1:35–38. (In Russ.)
  44. Kudaeva OT, Gojman EV, Nenasheva EV. Korrekcija autoimmunnogo glomerulonefrita u jeksperimental’nyh zhivotnyh letal’nym oblucheniem i perenosom kletok singennogo kostnogo mozga. Medicinskaja immunologija. 2010;12(3):191–198. (In Russ.)
  45. Weiping H, Huang G, Cao X, et al. Suppression of experimental autoimmune glomerulonephritis by tryptophan. J Nephrol. 2014;27:19–28. doi: 10.1007/s40620-013-0020-5
  46. Liu G, David BT, Trawczynski M, et al. Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. Stem Cell Rev Rep. 2020;16(1):3–32. doi: 10.1007/s12015-019-09935-x
  47. Zhao L, Chen S, Yang P, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10:182–195. doi: 10.1186/s13287-019-1287-9
  48. Korjakova NN. Patogeneticheskie osobennosti razlichnyh kliniko-morfologicheskih variantov hronicheskogo glomerulonefrita. Nefrologija. 2005;9:58–62. (In Russ.)
  49. Caldas HC, Couto T, Fernandes I et al. Comparative effects of mesenchymal stem cell therapy in distinct stages of chronic renal failure. Clin Exp Nephrol. 2015;19:783–789. doi: 10.1007/s10157-015-1079-1
  50. Reynolds J. Strain differences and the genetic basis of experimental autoimmune anti-glomerular basement membrane glomerulonephritis. Int J Exp Pathol. 2011;92:204–210. doi: 10.1111/j.1365-2613.2011.00763.x
  51. Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol. 2014;26:502–509. doi: 10.1097/BOR.0000000000000089
  52. Eunkyeong J, Jeong M, Kim S, et al. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development. Cell Transplantation. 2016;25:1–15. doi: 10.3727/096368915X688173
  53. Dandan W, Zhang H, Liang J, et al. Allogeneic Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus: 4 Years of Experience. Cell Transplantation. 2013;22:2267–2277. doi: 10.3727/096368911X582769c
  54. Chen C, Liang J, Yao G, et al. Mesenchymal stem cells upregulate Treg cells via sHLA-G in SLE patients. International Immunopharmacology. 2017;44:234–241. doi: 10.1016/j.intimp.2017.01.024
  55. Shuk-Man K, Sytwu H, Chang D, et al. Decoy Receptor 3 Ameliorates an Autoimmune Crescentic Glomerulonephritis Model in Mice. J Am Soc Nephrol. 2007;18:2473–2485. doi: 10.1681/ASN.2006111242
  56. Nagai H, Takizawa T, Nishiyori T, et al. Experimental glomerulonephritis in mice as a model for immunopharmacological studies. Japan. J Pharmacol. 1982;32:1117–1124. doi: 10.1254/jjp.32.1117
  57. Hiramatsu R, Ubara Y, Sawa N, et al. Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis. Human Pathology. 2016;50:187–194. doi: 10.1016/j.humpath.2015.12.005
  58. Chang A, Hingorani S, Kowalewska J, et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. Clin J Am Soc Nephrol. 2007;2:1014–1023. doi: 10.2215/CJN.01700407
  59. Kemper MJ, Güngör T, Halter J, et al. Favorable long-term outcome of nephrotic syndrome after allogeneic hematopoietic stem cell transplantation. Clin Nephrol. 2007;67:5–11. doi: 10.5414/cnp67005

Statistics

Views

Abstract: 151

Dimensions

Article Metrics

Metrics Loading ...

PlumX


Copyright (c) 2021 Sigareva L.P., Kokorina A.A., Kondartenko A.A., Slizhov P.A., Ekaterina E.V., Alexandrov V.N., Solovyov A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies